ADMA Biologics
ADMA
ADMA
130 hedge funds and large institutions have $315M invested in ADMA Biologics in 2022 Q3 according to their latest regulatory filings, with 28 funds opening new positions, 43 increasing their positions, 33 reducing their positions, and 11 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more first-time investments, than exits
New positions opened: | Existing positions closed:
more capital invested
Capital invested by funds: $ → $
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
15% more funds holding
Funds holding: 113 → 130 (+17)
5.37% more ownership
Funds ownership: 60.72% → 66.09% (+5.4%)
0% more funds holding in top 10
Funds holding in top 10: 4 → 4 (0)
Holders
130
Holding in Top 10
4
Calls
$3.82M
Puts
$965K
Top Buyers
| 1 | +$15.7M | |
| 2 | +$7.56M | |
| 3 | +$6.96M | |
| 4 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$5.31M |
| 5 |
Nuveen Asset Management
Chicago,
Illinois
|
+$3.75M |
Top Sellers
| 1 | -$10.1M | |
| 2 | -$6.05M | |
| 3 | -$5.44M | |
| 4 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
-$4.86M |
| 5 |
ACM
Altium Capital Management
New York
|
-$2.71M |